Flosonics Medical today announced a development contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. The contract supports FloPredict, an AI-enabled software enhancement to the company’s U.S. Food and Drug Administration (FDA)-cleared FloPatch device and extends the company’s real-time ultrasound technology into trauma care and mass casualty response.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901407038/en/

FloPatch, a wearable Doppler ultrasound device, is applied to the neck to measure real-time blood flow and help clinicians make faster, more personalized treatment decisions.

FloPatch, a wearable Doppler ultrasound device, is applied to the neck to measure real-time blood flow and help clinicians make faster, more personalized treatment decisions.

Through the contract, BARDA is funding the development of a capability to help clinicians detect internal bleeding after traumatic injury, work which is aimed at strengthening mass casualty response capabilities for events such as a nuclear detonation. The award, made through BARDA’s Burn and Blast Medical Countermeasures program, includes initial funding of approximately $15 million, with a total potential value of up to approximately $70 million if all options are exercised.

FloPatch is an FDA-cleared wireless Doppler ultrasound device that enables rapid, non-invasive, real-time hemodynamic assessment to help guide fluid resuscitation. The device has been used on more than 13,000 patients across more than 30 hospitals in the U.S., including routine use in sepsis, hypotension, and other critical care workflows where clinicians need timely insight into a patient’s likely response to fluids.

In collaboration with BARDA, Flosonics Medical will develop FloPredict, an AI algorithm designed to apply innovative hemodynamic analytics to the Doppler signals FloPatch collects. If successful, FloPredict could help clinicians identify patients at risk of complications from internal hemorrhage who may require urgent intervention. In trauma and mass casualty settings, where fast and objective information is scarce, that capability is intended to support quicker triage and better use of limited resources.

“Partnering with the U.S. government on a capability of this importance is a milestone for Flosonics,” says Joe Eibl, CEO and co-founder of Flosonics Medical. “There is a real gap in how clinicians detect internal bleeding in the critical minutes after injury, and this award lets us build toward closing it. It also reflects the broader potential of FloPatch: the same real-time assessment clinicians rely on in critical care today can be extended to the settings where fast answers matter most.”

“We built FloPatch so that any clinician could see a patient’s physiology in real time at the bedside, without waiting for a specialist. FloPredict will apply that same principle in trauma care,” says Jon-Emile Kenny, CMO and co-founder of Flosonics Medical. “The goal is software that recognizes hemodynamic patterns preceding deterioration from hemorrhage and surfaces them early enough to act on.”

About Flosonics Medical

Flosonics Medical is a medical device company engaged in the research and development of innovative ultrasound technology. Founded in 2015, the company’s mission is to improve patient care and the practice of medicine through technology-enabled solutions and groundbreaking clinical research. For more information, please visit www.flosonicsmedical.com.

This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50126C00006.

Media gallery

About The Author
Business Wire